TRICCAR announces results of first study of its Trigeminal Neuralgia Formula
Eighty-one percent reported decreased pain upon waking and seventy-three percent reported a decrease in pain lasting more than five hours after waking
Trigeminal neuralgia (TN), also called tic douloureux, is a chronic pain condition that affects the trigeminal cranial nerve, one of the most widely distributed nerves in the head. TN is a form of neuropathic pain. The typical or "classic" form of the disorder (called "Type 1" or TN1) causes extreme, sporadic, sudden burning or shock-like facial pain that lasts anywhere from a few seconds to as long as two minutes per episode. These attacks can occur in quick succession, in volleys lasting as long as two hours. The "atypical" form of the disorder (called "Type 2" or TN2), is characterized by constant aching, burning, stabbing pain. Both forms of pain may occur in the same person, sometimes at the same time.
Trigeminal neuralgia is a relatively rare disease, and many medical professionals have no knowledge of it. It is estimated that 1 in 15,000 to 20,000 people world-wide suffer from TN. The actual number may be higher as it is frequently misdiagnosed. Diagnosis is often delayed up to several years because TN can cause severe pain in the teeth, which leads to unnecessary dental treatment and tooth extractions. The incidence of new cases is approximately 12 per 100,000 people per year and the disorder is more common in women than in men.
The disease is usually treated through anticonvulsant medicines—used to block nerve firing—but are often less effective in TN2. These drugs include carbamazepine, oxcarbazepine, topiramate, gabapentin, pregabalin, clonazepam, phenytoin, lamotrigine, and valproic acid. Tricyclic antidepressants such as amitriptyline or nortriptyline may be used to treat pain. Common analgesics and opioids are not usually helpful in treating the sharp, recurring pain caused by TN. Eventually, if medication fails to relieve pain or produces intolerable side effects such as cognitive disturbances, memory loss, excess fatigue, bone marrow suppression, or allergy, then surgical treatment may be indicated. Since TN is a progressive disorder that often becomes resistant to medication over time, individuals often seek surgical treatment.
Bill Townsend, President and CEO of TRICCAR, said, "Trigeminal neuralgia is considered by many medical professionals to be the most painful disease known to mankind. Sufferers of TN often experience debilitating pain that far exceeds that of migraines, often rendering the patient unable to participate in daily activities, and in many cases, disabled and unable to hold a job. TRICCAR's Trigeminal Neuralgia Formula, also known as TNR©, which has been in development since early 2017, appears to be effective in reducing facial and nerve pain while providing deeper and uninterrupted sleep, allowing the body to better heal itself."
"While not considered a fatal disease, many who suffer from TN attempt or complete suicide, with a suicide completion rate of approximately 25% (double that of the general population), and because of this, TN is often called the 'Suicide Disease'," said Townsend. "It is our hope that continued research in ways to support those with the disease may result in an improved treatment protocol that can lessen the severity of TN."
The study results showed subjects taking TNR responded with the following benefits:
· 81% reported waking with decreased pain.
· 73% reported a decrease in pain of more than 5 hours after waking
· 52% reported decrease in pain of more than 8 hours after waking
· 58% reported deeper and longer sleep with an average increase of uninterrupted sleep from 4 hours to 7 hours
· 30% reported deeper and longer sleep with an average increase of uninterrupted sleep between 8 and 10 hours
· 2% reported uninterrupted sleep lasting over 10 hours, and,
· 4% reported no improvement in sleep.
TNR is taken in single capsule form 2 hours before bedtime. The Company next plans to conduct a larger double-blind study, followed by clinical studies.
TRICCAR is a Las Vegas, Nevada-based pharmaceutical and nutraceutical company targeting the world's most devastating diseases including obesity, cancer, pain, diabetic neuropathy, and cancer.
If you would like more information about this topic, please email email@example.com or through our website at http://www.triccar.com.